BioPharmSignal logoBioPharmSignal

Biotech News

Aprea Therapeutics to Present at October Conferences

Aprea Therapeutics (APRE)Aprea TherapeuticsConference / presentation

Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on

Related news

APREAprea Therapeutics2026-07-30 12:00 EST

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

APREAprea Therapeutics2026-09-22 12:30 EST

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

EXELExelixis2026-09-01 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

View all latest news

Aprea Therapeutics

DNA Damage Response Oncology Aprea Therapeutics develops precision medicines that exploit vulnerabilities in cancer-cell DNA replication and repair. Its programs target biomarker-defined tumors while seeking to limit effects on healthy cells. APR-1051 APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for...

Recent company news

APREAprea Therapeutics2026-10-05 12:30 EST

Aprea Therapeutics to Present at October Conferences

APREAprea Therapeutics2026-09-22 12:30 EST

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

APREAprea Therapeutics2026-09-22 12:30 EST

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

APREAprea Therapeutics2026-09-10 12:00 EST

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

APREAprea Therapeutics2026-09-10 12:00 EST

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Stock data

Close
0.72 USD
Market cap
9.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States